2215 Yukon Street
Vancouver, BC V5Y 0A1
Full-time employees: 475
|Dr. Carl L.G. Hansen Ph.D.||CEO, Pres & Chairperson||616.66k||2.77M||1975|
|Mr. Andrew Booth M.B.A.||Chief Financial Officer||563.57k||37.12M||1974|
|Dr. Veronique Lecault Ph.D.||COO & Director||563.57k||13.19M||1985|
|Mr. Tryn T. Stimart Esq., J.D.||Chief Legal Officer, Chief Compliance Officer & Corp. Sec.||563.8k||24.68M||1970|
|Dr. Ester Falconer Ph.D.||Chief Technology Officer||N/A||N/A||1975|
|Mr. Bo Barnhart Ph.D.||Scientific Director||N/A||N/A||N/A|
|Ms. Tiffany Chiu B.Sc., Ph.D.||VP of Communications||N/A||N/A||N/A|
|Alexandra Weirich M.Sc.||Mang. of Marketing & Communications||N/A||N/A||N/A|
|Graham Craig M.Sc.||Director of Corp. Devel.||N/A||N/A||N/A|
|Caitlin Webster CIPD, M.Sc.||Sr. Mang. of People & Culture||N/A||N/A||N/A|
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
AbCellera Biologics Inc.’s ISS governance QualityScore as of 1 February 2023 is 8. The pillar scores are Audit: 9; Board: 10; Shareholder rights: 4; Compensation: 8.